Cargando…
Knowledge-based repositioning of the anti-HCV direct antiviral agent Sofosbuvir as SARS-CoV-2 treatment
The new human coronavirus named SARS-CoV-2 is a positive-sense RNA virus for which no specific drugs are currently available. A knowledge-based analysis strongly suggests a possible repositioning of the anti-HCV direct antiviral agent (DAA) Sofosbuvir as treatment for SARS-CoV-2. Indeed, the RNA-dep...
Autores principales: | Buonaguro, Luigi, Buonaguro, Franco M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7215134/ https://www.ncbi.nlm.nih.gov/pubmed/32419838 http://dx.doi.org/10.1186/s13027-020-00302-x |
Ejemplares similares
-
SARS-CoV-2 RNA polymerase as target for antiviral therapy
por: Buonaguro, Luigi, et al.
Publicado: (2020) -
The Role of Circulating Free DNA and MicroRNA in Non-Invasive Diagnosis of HBV- and HCV-Related Hepatocellular Carcinoma
por: Pezzuto, Francesca, et al.
Publicado: (2018) -
Molecular Signatures Associated with HCV-Induced Hepatocellular Carcinoma and Liver Metastasis
por: De Giorgi, Valeria, et al.
Publicado: (2013) -
New Insights in the Design of Bioactive Peptides and Chelating Agents for Imaging and Therapy in Oncology
por: Tornesello, Anna Lucia, et al.
Publicado: (2017) -
Sofosbuvir/velpatasvir in treatment-experienced HCV-infected patients – short report
por: Piekarska, Anna, et al.
Publicado: (2020)